Tejas Savant
Stock Analyst at Morgan Stanley
(2.37)
# 2,573
Out of 5,237 analysts
248
Total ratings
43.75%
Success rate
-0.88%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $6 → $5.5 | $4.09 | +34.47% | 10 | May 12, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $21 → $18 | $13.33 | +35.03% | 14 | May 12, 2026 | |
| TXG 10x Genomics | Maintains: Equal-Weight | $20 → $22 | $20.56 | +7.00% | 17 | May 12, 2026 | |
| VCYT Veracyte | Maintains: Underweight | $48 → $37 | $39.23 | -5.68% | 16 | Mar 6, 2026 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $24 → $19 | $18.46 | +2.93% | 4 | Mar 6, 2026 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $10 | $5.74 | +74.22% | 15 | Mar 5, 2026 | |
| TEM Tempus AI | Maintains: Overweight | $85 → $70 | $46.08 | +51.91% | 7 | Mar 3, 2026 | |
| NTRA Natera | Maintains: Overweight | $265 → $250 | $201.93 | +23.81% | 16 | Mar 3, 2026 | |
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $59.71 | +0.49% | 4 | Feb 24, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $460.00 | +45.65% | 16 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $265 | $175.54 | +50.97% | 12 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $143.86 | -27.01% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $8.13 | +47.60% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $8.74 | -8.41% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $12.83 | -45.44% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $4.69 | +6.61% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $4.16 | +404.81% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.31 | +52.67% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.50 | +370.59% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.89 | +107.61% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.66 | +114.59% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.57 | +7.21% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.83 | +447.95% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $95.84 | -23.83% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $169.57 | +47.43% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $15.50 | +545.16% | 5 | May 12, 2022 |
Cytek Biosciences
May 12, 2026
Maintains: Equal-Weight
Price Target: $6 → $5.5
Current: $4.09
Upside: +34.47%
Adaptive Biotechnologies
May 12, 2026
Maintains: Equal-Weight
Price Target: $21 → $18
Current: $13.33
Upside: +35.03%
10x Genomics
May 12, 2026
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $20.56
Upside: +7.00%
Veracyte
Mar 6, 2026
Maintains: Underweight
Price Target: $48 → $37
Current: $39.23
Upside: -5.68%
Stevanato Group
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $24 → $19
Current: $18.46
Upside: +2.93%
Personalis
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $5.74
Upside: +74.22%
Tempus AI
Mar 3, 2026
Maintains: Overweight
Price Target: $85 → $70
Current: $46.08
Upside: +51.91%
Natera
Mar 3, 2026
Maintains: Overweight
Price Target: $265 → $250
Current: $201.93
Upside: +23.81%
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $59.71
Upside: +0.49%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $460.00
Upside: +45.65%
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $175.54
Upside: +50.97%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $143.86
Upside: -27.01%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $8.13
Upside: +47.60%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $8.74
Upside: -8.41%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $12.83
Upside: -45.44%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.69
Upside: +6.61%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $4.16
Upside: +404.81%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.31
Upside: +52.67%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.50
Upside: +370.59%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.89
Upside: +107.61%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.66
Upside: +114.59%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.57
Upside: +7.21%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.83
Upside: +447.95%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $95.84
Upside: -23.83%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $169.57
Upside: +47.43%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $15.50
Upside: +545.16%